Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 50,965Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Afrezza

02 4Human Insulins

03 3Humulin

04 5Insuman

05 1Levemir

06 1Modern Insulins (Insulin analogues)

07 1New-Generation Insulin

08 2New-generation Insulin

09 1NovoMix/ NovoLog Mix

10 1NovoRapid/NovoLog

11 1Total Modern Insulins

12 5Xultophy

PharmaCompass

01

Brand Name : Insuman

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2014 Revenue in Millions : 3.80%

2013 Revenue in Millions :

Growth (%) :

Sanofi Company Banner

02

Brand Name : Insuman

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 151

2014 Revenue in Millions : 155

Growth (%) : 3%

Sanofi Company Banner

03

Brand Name : Afrezza

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

insulin human

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 8

Growth (%) : New Launch

Sanofi Company Banner

04

Brand Name : Insuman

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2016 Revenue in Millions : 137

2015 Revenue in Millions : 149

Growth (%) : -9

Sanofi Company Banner

05

Brand Name : Afrezza

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin Human

Main Therapeutic Indication : Diabetes

Currency : USD

2016 Revenue in Millions : Not Reported

2015 Revenue in Millions : 7

Growth (%) : -100

Sanofi Company Banner

06

Brand Name : Insuman

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2017 Revenue in Millions : 133

2016 Revenue in Millions : 160

Growth (%) : -17

Sanofi Company Banner

07

Brand Name : Insuman

arrow
Antibody Engineering
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2018 Revenue in Millions : 0

2017 Revenue in Millions : 121

Growth (%) : -100%

Sanofi Company Banner

08

Brand Name : Xultophy

Insulin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Xultophy

arrow
Antibody Engineering
Not Confirmed

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 398

2019 Revenue in Millions : 359

Growth (%) : 11

blank

09

Brand Name : Xultophy

Insulin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Xultophy

arrow
Antibody Engineering
Not Confirmed

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 405

2020 Revenue in Millions : 391

Growth (%) : 9

blank

10

Brand Name : Xultophy

Insulin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Xultophy

arrow
Antibody Engineering
Not Confirmed

Insulin

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 410

2021 Revenue in Millions : 405

Growth (%) : 1

blank